Dr. Goetz on Adjuvant Capecitabine Following Neoadjuvant Chemotherapy and Surgery
Matthew Goetz, MD, medical oncologist, professor of Oncology, associate professor of Pharmacology, andprofessor of Pharmacology at Mayo Clinic, discusses a phase III study looking at capecitabine (Xeloda) in patients with residual breast cancer following neoadjuvant chemotherapy and surgery.
Matthew Goetz, MD, medical oncologist, professor of Oncology, associate professor of Pharmacology, and professor of Pharmacology, Mayo Clinic, discusses a phase III study looking at capecitabine (Xeloda) in patients with residual breast cancer following neoadjuvant chemotherapy and surgery.
The study found that the disease-free survival rate with capecitabine was 74.1% versus 67.6% with standard therapy alone and overall survival for patients receiving capecitabine was 89.2% compared with 83.9% for those in the standard therapy arm, after 5 years of follow-up.
These findings are not only statistically significant, but clinically significant, says Goetz.
This study suggests that, going forward, it may be beneficial to consider taking a neoadjuvant chemotherapy approach before identifying which patients respond to chemotherapy and determining which may be eligible for capecitabine, says Goetz.
<<<
